EC expands approval of Reblozyl to first-line treatment of anemia in MDS – The Cancer Letter
The European Commission expanded the indication of Reblozyl (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low, and intermediate-risk myelodysplastic syndromes. This approval of Reblozyl covers all EU member states. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP […]